VRNA
NASDAQVerona Pharma plc
Price$106.91+15.43 (+16.87%)
2025-07-032025-10-06
News · 26 weeks40%
2025-11-022026-04-26
Mix090d
No activity.
Latest news
25 items- SECSEC Form EFFECT filed by Verona Pharma plcEFFECT - Verona Pharma plc (0001657312) (Filer)
- SECSEC Form SCHEDULE 13G filed by Verona Pharma plcSCHEDULE 13G - Verona Pharma plc (0001657312) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plcSCHEDULE 13G/A - Verona Pharma plc (0001657312) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plcSCHEDULE 13G/A - Verona Pharma plc (0001657312) (Subject)
- SECSEC Form 15-12G filed by Verona Pharma plc15-12G - Verona Pharma plc (0001657312) (Filer)
- INSIDERGeneral Counsel Fisher Andrew returned 1,349,887 units of Ordinary Shares to the company and converted options into 931,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERPresident and CEO Zaccardelli David returned 15,461,424 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERChief Medical Officer Rickard Kathleen A. returned 3,564,852 units of Ordinary Shares to the company and converted options into 1,131,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERChief Financial Officer Hahn Mark W returned 14,550,248 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Austwick Michael returned 84,712 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Ullman Anders returned 430,856 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Shah Mahendra returned 165,472 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Sinha Vikas returned 166,112 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Deschamps Lisa returned 156,856 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Ebsworth David R returned 1,570,099 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Edwards Martin returned 229,992 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Brady James Aloysius returned 95,176 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Cunningham Kenneth returned 151,776 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- INSIDERDirector Ackermann Christina returned 136,072 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- SECSEC Form S-8 POS filed by Verona Pharma plcS-8 POS - Verona Pharma plc (0001657312) (Filer)
- SECSEC Form S-8 POS filed by Verona Pharma plcS-8 POS - Verona Pharma plc (0001657312) (Filer)
- SECSEC Form S-8 POS filed by Verona Pharma plcS-8 POS - Verona Pharma plc (0001657312) (Filer)
- SECSEC Form POSASR filed by Verona Pharma plcPOSASR - Verona Pharma plc (0001657312) (Filer)
- SECSEC Form S-8 POS filed by Verona Pharma plcS-8 POS - Verona Pharma plc (0001657312) (Filer)
- SECSEC Form S-8 POS filed by Verona Pharma plcS-8 POS - Verona Pharma plc (0001657312) (Filer)
VRNA FAQ
7 questionsWhat does Verona Pharma plc do?
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including...Where does VRNA stock trade?
Verona Pharma plc (VRNA) is listed on NASDAQ.What sector and industry is VRNA in?
Verona Pharma plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Verona Pharma plc go public?
Verona Pharma plc (VRNA) completed its IPO in 2017.What are analysts saying about VRNA?
Verona Pharma plc has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2025-07-14. Recent price targets range from $2700.00 to $3800.00.What companies are similar to VRNA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare VRNA side-by-side with any of them on Quantisnow.How can I track VRNA on Quantisnow?
Quantisnow aggregates Verona Pharma plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRNA to receive live email and push alerts on every new disclosure.